Kaipu Bio disclosed its 2026 semi-annual report. In the first half, net profit attributable to shareholders of the listed company was 31.2621 million yuan, compared with a loss of 89.5914 million yuan in the same period last year, turning from loss to profit year-on-year. The company achieved total operating revenue of 300 million yuan in the first half, down 4.74 percent year-on-year, with basic earnings per share of 0.0484 yuan. During the reporting period, the company reversed credit impairment losses of 30.4456 million yuan and made asset impairment provisions of 437,500 yuan. Credit impairment losses and asset impairment losses decreased by 88.0096 million yuan and 10.4566 million yuan respectively compared with the same period last year. Combined with factors such as increased exchange gains and reduced selling expenses in the current period, these jointly drove net profit attributable to shareholders of the listed company to increase by 121 million yuan compared with the same period last year.
Guangdong Hybribio Biotech Co LtdFirst-half net profit turned to profit of 31.26 million yuan from a loss, driven by reduced impairments and costs.
